April 11, 2025 | Shanghai — SIMR Biotech announced today that its abstract titled “Novel Therapeutic for Diabetic Kidney Disease through Targeting Lp-PLA2 in Immune Cells and Damaged Renal Parenchymal Cells” has been accepted as a Focused Oral Presentation at the 62nd European Renal Association (ERA) Congress, to be held June 4-7 in Vienna, Austria.
The presentation will spotlight SR1375’s immune-modulating mechanism and its protective effects on glomerular and tubular epithelial cells, offering a novel strategy for halting progression of diabetic kidney disease (DKD).
“SR1375 represents a first-in-class approach to treating DKD by targeting inflammation at the root of both vascular and parenchymal damage,” said Dr. Li Shuai, CEO of SIMR Biotech. “We’re honored to present our findings at ERA 2025 and contribute to the global conversation on kidney innovation.”
ERA 2025 Presentation Details:
Session: Chronic Kidney Disease
Date/Time: June 6, 2025 | 15:06–15:12 CEST
Room: Focused Oral Room 10
Title: “Novel Therapeutic for Diabetic Kidney Disease through Targeting Lp-PLA2 in Immune Cells and Damaged Renal Parenchymal Cells”
About SR1375 in Renal Disease:
SR1375 modulates the Lp-PLA2 axis, reducing inflammatory cell infiltration, preserving renal endothelial integrity, and limiting renal fibrosis. Currently, the drug has received IND approval for the diabetic kidney disease (DKD) indication in China NMPA and is set to advance to Phase II clinical trials.
